• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Nanobac Pharmaceuticals Inc. Announces Agreement to Validate Proof That Nanobacteria Promote Gallstones

Posted on: Wednesday, 23 August 2006, 09:00 CDT

Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") today announced that it has entered into an agreement and started work on an animal model to validate a proof of concept that calcifying nanoparticles (CNPs), also known as nanobacteria, promote gallstones.

If the proof is validated, it will solve the ages-old mystery of what provokes black pigment gallstones affecting millions of persons, and forge a path to effective early diagnosis and therapy where none are presently available. Results are expected by year-end 2006. Because these gallstones contain material similar to that in kidney stones and breast cancer calcifications, the results could apply to other unsolved calcification-related conditions as well.

The agreement was signed with the same scientific team who, in "An Animal Model of Black Pigment Gallstones Caused by Nanobacteria" published in the June 2006 edition of the peer-reviewed journal Digestive Diseases and Sciences, established that calcifying nanoparticles promote black pigment gallstones in rabbits when injected into the gallbladder.

The study concludes, "We successfully cultured nano-sized particles coated with hydroxyapatite from human gallbladder bile and confirmed that they were nanobacteria by their typical growth rates, optical properties, specific stainability with Hoechst 33258, and by immunologic methods. By the animal experiment, we demonstrated for the first time that black pigment gallstones could be promoted by nanobacterial infection."

The initial study was conducted independent of Nanobac Pharmaceuticals and was not funded from any corporate source. Abstract of that study is available at PubMed by entering the study title at this website: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed

The Principle Investigator is Dr. LiMin Wang, from Shantou University Medical College, Guangdong, China. Results will be verified by a team consisting of a former Merck executive and other U.S. experts in urology and infectious diseases.

Nanobac is the only Company with regulatory approval of diagnostics that can accurately identify these calcifying particles. The Company is also expecting to start a clinical trial on a promising therapy for such stone-forming diseases by the fourth quarter of 2006.

About Nanobac Pharmaceuticals

Nanobac Pharmaceuticals, Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting Calcifying Nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com .

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes,""anticipates,""intends,""plans,""expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

Source: Business Wire

More News in this Category